Mogling Bio Inc., a privately owned, preclinical stage biopharmaceutical company, announced it has entered into a global and exclusive licensing agreement with Cincinnati Children’s Hospital Medical Center for CASIN, a CDC 42 inhibitor being developed for rejuvenation of hematopoietic stem cells. Mogling Bio stated this might become a treatment option for certain forms of leukemia, or to improve the functioning of patients’ immune systems.

Under the terms of the agreement, Mogling Bio has exclusive rights to develop, manufacture and commercialize CASIN worldwide. Financial terms with Cincinnati Children’s weren’t disclosed. 

“We are pleased to have reached this agreement with Cincinnati Children’s,” said Juergen Reess, Mogling Bio’s CEO. “CDC42 inhibitors like CASIN have shown astonishing preclinical results. This agreement will help us on our goal to translate these findings into treatment options for patients in need.”